4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments

US7727989B2 · kind B2 · utility

Assignee

• Sanofi-Aventis Deutschland GMBH · DE

Inventors

• Karl Schoenafinger · Alzenau, DE
• Swen Hoelder · London, GB
• David William Will · Schwalbach, DE
• Hans Matter · Langenselbold, DE
• Guenter Mueller · Pocking, DE
• Martin Bossart · Frankfurt am Main, DE

Key dates

• Filing date: Aug 28, 2006
• Grant date: Jun 1, 2010
• Expiry date: Aug 28, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to kinase inhibitor compounds and derivatives thereof as well as compositions comprising them consisting of the structure of formula I:Wherein R1, R2, A, B, D and E are defined herein. These 4-benzimidazol-2-ylpyridazin-3-ones and their derivatives and compositions comprising them are useful in the treatment of neurological disorders such as Alzheimers' disease, Parkinsons' disease, obesity, hypertension and the like. These pyridazinone derivatives particularly inhibit the metabolic activity of glycogen synthase kinase-3 β (GSK-3β) which is believed to cause the neurodegeneration that results in these diseases.